NCT06962332View on ClinicalTrials.gov

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Hepatic ImpairmentModerate Hepatic Impairment
Interventions
DRUG

Zanzalintinib

Administered as specified in the treatment arm.

Trial Locations (2)

32809

RECRUITING

Exelixis Clinical Site #1, Orlando

78215

RECRUITING

Exelixis Clinical Site #2, San Antonio

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY

NCT06962332 - Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | Biotech Hunter | Biotech Hunter